Navigation Links
Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
Date:6/15/2011

COPENHAGEN, Denmark and INGELHEIM, Germany, June 16, 2011 /PRNewswire/ --


 

- Boehringer Ingelheim Obtains Global Rights to glucagon/GLP-1 Dual Agonists, including ZP2929, Zealand Pharma's Lead Drug Candidate in This Class


- Zealand Pharma is Eligibleto Receive Total Projected Milestone Payments
of up to €376 million for ZP2929

 

Today, Zealand Pharma (NASDAQ OMX: ZEAL), a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

As part of the agreement, Boehringer Ingelheim obtains global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first Phase I study with ZP2929 and Boehringer Ingelheim will fund the research, development and commercialisation of products under the agreement.

Depending on the achievement of pre-defined development, regulatory and commercial milestones, Zealand Pharma is eligible to receive payments for ZP2929 and may also receive additional milestone payments if other products covered by the collaboration are advanced through development. Further, Zealand Pharma is entitled to tiered royalties that range from high single to low double digits on global sales of products under the agreement. Zealand Pharma retains co-promotion rights in Scandinavia.

During the first two years of collaboration, Zealand Pharma is eligible to receive sig
'/>"/>

SOURCE Zealand Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand
2. Prostate Cancer Patients Benefit from New Zealand Centers Adoption of Elekta VMAT Radiotherapy Technique
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
4. Successful Clinical Trials and Launch in New Zealand Spurs Phloe to Enter US Market
5. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
6. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
7. Saint-Gobains New C-Flex® ULTRA Pump Tubing for Biopharmaceutical Applications Outperforms the Competition
8. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
9. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
10. Caraco Announces Stockholder Approval of Merger Agreement with Sun Pharma and Consummation of the Merger
11. Cardinal Health Extends Radiopharmaceutical Manufacturing Network, Opening its First Cyclotron in Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Spain , April 25, 2015  With the ... benefits of precision cranial radiosurgery are now available for ... and sizes. This latest generation stereotactic radiosurgery system for ... imaging technologies, significantly increasing the versatility of Gamma Knife ... the 3 rd ESTRO Forum in ...
(Date:4/24/2015)... -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, ... from Mylan NV ("Mylan") (NASDAQ: MYL ) to ... $60.00 per share in cash and 2.2 Mylan ordinary ... The Board previously concluded that Mylan,s unsolicited ... and its future growth prospects and was not in ...
(Date:4/24/2015)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, announced the Company will hold a conference call ... to discuss the 1st quarter 2015 results. ... by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canadian ... joined into the IGI Laboratories, Inc. call. ...
Breaking Medicine Technology:New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... 2015 Bird B Gone, the leader in ... offers a complete line of bird control solutions to address ... New Flu Strains Threaten Pacific, Central and Mississippi Farms , ... , a number of highly pathogenic avian flus in the ... often spread when wild birds enter poultry farms. The USDA ...
(Date:4/24/2015)... Ryadon is a leading manufacturer of custom ... services to complement any custom hardware requirements you may ... be offered on all heavy duty drawer slides ( ... discount - Order 20+: Receive 20% discount , Industries ... Furniture ,Drawer Slides, Inc. ...
(Date:4/24/2015)... 2015 The 1975 have had ... across the globe to theaters, festivals and TV performances. Now ... partnered with their label, Dirty Hit Records, to provide clean ... the newly launched Cadence & Cause website, this ... on vinyl and a signed photo card. Entries from ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... 28 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... two new,additions to its Iceland Health(R) brand portfolio: ... Plus SLEEP Support.,Formulated with omega-3 fish oil and ...
... Noor came to,the attention of the Battalion Commander of ... Brigade Combat Team through an,unfortunate shooting incident from a ... little girl,s uncle. The initial diagnosis made by Lt.,Col. ... blind,due to a birth defect that resulted in poorly ...
... 28 OrbusNeich today announced that it,has received approval ... R stent in Taiwan., The Genous stent is ... cells (EPCs) circulating in the bloodstream. When,attracted to the ... shown to,quickly form a healthy layer of endothelium that ...
... 28 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... New Drug Application (NDA) for oxybutynin,chloride topical gel ... U.S. Food,and Drug Administration (FDA). Watson is seeking ... hydrochloride for the treatment of,overactive bladder (OAB)., ...
... account for nearly all of the increase in U.S. singleton ... national birth data. , Between 1996 and 2004 there ... 92 percent of those infants were delivered by a cesarean ... of Dimes and the U.S. Centers for Disease Control and ...
... 27 It is estimated that there were ... Did you know that,African-American women have a 50 ... A new campaign, One4One, is empowering women to,help ... increase cervical,cancer education programs for women in multicultural ...
Cached Medicine News:Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 2Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 3Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 4Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2Health News:OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 3Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 4Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 5Health News:C-sections a critical factor in preterm birth increase 2
Inquire...
Benchtop UV Incubator is designed to provide precise temperature control and uniformity throughout the chamber. Decontaminate chamber between experiments with built-in shortwave UV....
Inquire...
Inquire...
Medicine Products: